Estrogen, in context.

Estradiol is the dominant estrogen in adults of both sexes. It maintains bone density, regulates lipid handling and vascular function, and drives libido, mood stability and sleep architecture. In men it is produced by the aromatization of testosterone, which is why the two can never be interpreted separately.

• Bone mineral density — the clearest long-term consequence of chronically low estradiol in either sex.
• Cardiovascular and lipid handling, including HDL and endothelial function.
• Sleep architecture, thermoregulation and vasomotor symptoms.
• Cognition, mood and libido, which frequently shift before any other marker moves.

Perimenopause can run for a decade before the final period, and estradiol during that window swings dramatically across and between cycles. A single in-range draw says almost nothing. We read estradiol, FSH, LH, progesterone, SHBG and testosterone against your cycle history and your symptoms — sleep disruption, cycle change, mood volatility, joint pain and brain fog.

The longer version is in perimenopause and hormone therapy.

Suppressing estradiol with an aromatase inhibitor is one of the most common errors in testosterone therapy. Joint pain, flat mood, absent libido and accelerating bone loss are the predictable results. The target is a proportionate estradiol relative to testosterone, achieved by adjusting the testosterone dose first.

The companion page is testosterone, read properly.

• Transdermal estradiol — patch or gel — preferred over oral to bypass first-pass liver metabolism.
• Micronized progesterone alongside estradiol for anyone with a uterus, to protect the endometrium.
• Low-dose testosterone considered in women for libido, energy and lean mass where clinically appropriate.
• Follow-up labs and symptom review at eight to twelve weeks, then periodically, with dose titrated to response.

How the full program runs is described on hormone therapy in Chicago.

For most healthy women starting within ten years of menopause and under age 60, guideline bodies find benefits generally outweigh risks. That is a population statement, not a personal one. Personal and family history of breast cancer, clotting disorders, liver disease and cardiovascular disease all change the decision, and all of it is reviewed before anything is prescribed.